Life science focused Vida Ventures is advancing on its goal of raising $600 million for its second VC fund. According to a recent... read more
Life science focused Vida Ventures is advancing on its goal of raising $600 million for its second VC fund. According to a recent... read more
Clinical stage biopharma, Xynomic Pharma, filed the paperwork for a new $65 Million offering. The company is developing small molecule treatments for several different cancer types. It trades on... read more
Clinical stage biopharma RAPT Therapeutics filed the paperwork for its IPO on 6/5/19. The company is focused on developing therapies targeting immune drivers of cancer and inflammation. They... read more
Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today the award of an Innovate UK grant to CHAIN Biotech Ltd (CHAIN) and... read more
While the pharmaceutical industry is a fast-growing sector of healthcare, different types of fraud are committed and reported to the government.... read more
Livongo Health, a company focused on aiding those with chronic conditions, filed for a $100 million IPO on 6/28/19. The initial filing does not specify the number of shares to be offered. The... read more
Castle Biosciences Filed the paperwork on 6/26/19 for their $57 Million IPO. The commercial stage company provides diagnostic and prognostic test for dermatologic cancers. Castle intends to... read more
Adaptive updated their IPO filing on 6/26/19 and raised their potential raise to $327 million from $230 million listed in their original filing. The company currently offers tools for monitoring... read more
Vesalius Biocapital III ('Vesalius'), a specialist life sciences venture capital investor, announced on 6/25/19 the final close of the VBC III fund securing EUR 120 million of equity commitments.... read more
Fulcrum Therapeutics filed the paperwork for there IPO to raise up to $86 million on 6/21/19. The company has three small molecule candidates in development that aim to treat the root cause of a... read more
Karuna Therapeutics updated its IPO filing to include a new maximum of $85 million+. The company will offer 4,375,000 shares. The company plans to trade on NASDAQ... read more
Change Healthcare, which provides healthcare revenue cycle management software and services, announced terms for its IPO and equity offering on 6/14/19. The company will raise up to $900 million+... read more
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring... read more
Dermavant updated its filing on 6/10/19 and will issue 7,700,000 shares and raise up to $123.9 million. Roivant is the controlling shareholder and will have the right to appoint two directors to... read more
Precision immuno-oncology medicine company, Personalis, updated their IPO filing on 6/7/19. The company plans to offer 6,666,667 shares and raise up to $122+ million. Personalis plans to trade on... read more
As investor interest in early stage life science companies continues to grow, Third Rock has announced the closing of an oversubscribed fund focused on discovering, launching and building... read more
